Bioversys bags €17.7m financingSwiss BioVersys AG has secured a CHF19m Series B financing to push clinincal development of two antiinfectives against drug-resistant pathogens. more ➔
Sotio licences Unum Therapeutics CAR-T c...PPF-owned company SOTIO has acquired the rights to use the BOXR CAR-T platform and products from Cambridge-based Unum Therapeutics. more ➔
Polyphor partners with Fosun Pharma Polyphor AG has licenced its metastatic cancer drug balixafortide to Fosun Pharma Co Ltd to market the drug exclusively in China. more ➔
Engitix Ltd. lands US$500m deal with Taked...British fibrosis therapeutics start-up Engitix Ltd has entered a collaboration agreement with Takeda to develop anti-fibrotic therapies in liver diseases. more ➔
Moderna set to deliver COVID-19 jab to the...US experiemental mRNA vaccine maker Moderna Inc is in advanced talks with the European Commission to supply 80 million doses mRNA-1273, its candidate vs SARS-CoV-2 more ➔
Scientists map ulcerative colitisScientists from Leuven, Rotterdam and San Diego have published a sequencing-based map of ulcerative colitis paving the way to new treatments. more ➔
COVID-19: Roche and Regeneron join forcesRoche and Regeneron have signed an manufacturing and distribution agreement on Regenerons Phase II therapeutic antibody for the treatment of COVID-19. more ➔
Aicuris to launch AiCubator to fight AMRAntinfectives specialist AiCuris GmbH will launch the AiCubator, a new way to collaborate in anti-infectives and support novel approaches, at the 4th AMR Conference. more ➔
Cell-based vaccination vs mortality-reduci... Immunovative Therapies Ltd and its US subsidiary Mirror Biologics Inc. are testing a novel, T cell-based vaccination concept that might protect risk groups from new SARS-CoV-2 variants and any emerging … more ➔
AI predicts mutations underlying neurologi... Using data from more than 20,000 patients with neurological diseases, researchers have established an algorithm that predicts whether mutations in ion channels will cause disease. more ➔
